Arteriovenous Access Type and Risk of Mortality, Hospitalization, and Sepsis Among Elderly Hemodialysis Patients: A Target Trial Emulation Approach
Evidence is mixed regarding the optimal choice of the first permanent vascular access for elderly patients receiving hemodialysis (HD). Lacking data from randomized controlled trials, we used a target trial emulation approach to compare arteriovenous fistula (AVF) versus arteriovenous graft (AVG) cr...
Saved in:
| Published in: | American journal of kidney diseases Vol. 79; no. 1; p. 69 |
|---|---|
| Main Authors: | , , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
United States
01.01.2022
|
| Subjects: | |
| ISSN: | 1523-6838, 1523-6838 |
| Online Access: | Get more information |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | Evidence is mixed regarding the optimal choice of the first permanent vascular access for elderly patients receiving hemodialysis (HD). Lacking data from randomized controlled trials, we used a target trial emulation approach to compare arteriovenous fistula (AVF) versus arteriovenous graft (AVG) creation among elderly patients receiving HD.
Retrospective cohort study.
Elderly patients included in the US Renal Data System who initiated HD with a catheter and had an AVF or AVG created within 6 months of starting HD.
Creation of an AVF versus an AVG as the incident arteriovenous access.
All-cause mortality, all-cause and cause-specific hospitalization, and sepsis.
Target trial emulation approach, high-dimensional propensity score and inverse probability of treatment weighting, and instrumental variable analysis using the proclivity of the operating physician to create a fistula as the instrumental variable.
A total of 19,867 patients were included, with 80.1% receiving an AVF and 19.9% an AVG. In unweighted analysis, AVF creation was associated with significantly lower risks of mortality and hospitalization, especially within 6 months after vascular access creation. In inverse probability of treatment weighting analysis, AVF creation was associated with lower incidences of mortality and hospitalization within 6 months after creation (hazard ratios of 0.82 [95% CI, 0.75-0.91] and 0.82 [95% CI, 0.78-0.87] for mortality and all-cause hospitalization, respectively), but not between 6 months and 3 years after access creation. No association between AVF creation and mortality, sepsis, or all-cause, cardiovascular disease-related, or infection-related hospitalization was found in instrumental variable analyses. However, AVF creation was associated with a lower risk of access-related hospitalization not due to infection.
Potential for unmeasured confounding, analyses limited to elderly patients, and absence of data on actual access use during follow-up.
Using observational data to emulate a target randomized controlled trial, the type of initial arteriovenous access created was not associated with the risks of mortality, sepsis, or all-cause, cardiovascular disease-related, or infection-related hospitalization among elderly patients who initiated HD with a catheter. |
|---|---|
| AbstractList | Evidence is mixed regarding the optimal choice of the first permanent vascular access for elderly patients receiving hemodialysis (HD). Lacking data from randomized controlled trials, we used a target trial emulation approach to compare arteriovenous fistula (AVF) versus arteriovenous graft (AVG) creation among elderly patients receiving HD.
Retrospective cohort study.
Elderly patients included in the US Renal Data System who initiated HD with a catheter and had an AVF or AVG created within 6 months of starting HD.
Creation of an AVF versus an AVG as the incident arteriovenous access.
All-cause mortality, all-cause and cause-specific hospitalization, and sepsis.
Target trial emulation approach, high-dimensional propensity score and inverse probability of treatment weighting, and instrumental variable analysis using the proclivity of the operating physician to create a fistula as the instrumental variable.
A total of 19,867 patients were included, with 80.1% receiving an AVF and 19.9% an AVG. In unweighted analysis, AVF creation was associated with significantly lower risks of mortality and hospitalization, especially within 6 months after vascular access creation. In inverse probability of treatment weighting analysis, AVF creation was associated with lower incidences of mortality and hospitalization within 6 months after creation (hazard ratios of 0.82 [95% CI, 0.75-0.91] and 0.82 [95% CI, 0.78-0.87] for mortality and all-cause hospitalization, respectively), but not between 6 months and 3 years after access creation. No association between AVF creation and mortality, sepsis, or all-cause, cardiovascular disease-related, or infection-related hospitalization was found in instrumental variable analyses. However, AVF creation was associated with a lower risk of access-related hospitalization not due to infection.
Potential for unmeasured confounding, analyses limited to elderly patients, and absence of data on actual access use during follow-up.
Using observational data to emulate a target randomized controlled trial, the type of initial arteriovenous access created was not associated with the risks of mortality, sepsis, or all-cause, cardiovascular disease-related, or infection-related hospitalization among elderly patients who initiated HD with a catheter. Evidence is mixed regarding the optimal choice of the first permanent vascular access for elderly patients receiving hemodialysis (HD). Lacking data from randomized controlled trials, we used a target trial emulation approach to compare arteriovenous fistula (AVF) versus arteriovenous graft (AVG) creation among elderly patients receiving HD.RATIONALE & OBJECTIVEEvidence is mixed regarding the optimal choice of the first permanent vascular access for elderly patients receiving hemodialysis (HD). Lacking data from randomized controlled trials, we used a target trial emulation approach to compare arteriovenous fistula (AVF) versus arteriovenous graft (AVG) creation among elderly patients receiving HD.Retrospective cohort study.STUDY DESIGNRetrospective cohort study.Elderly patients included in the US Renal Data System who initiated HD with a catheter and had an AVF or AVG created within 6 months of starting HD.SETTING & PARTICIPANTSElderly patients included in the US Renal Data System who initiated HD with a catheter and had an AVF or AVG created within 6 months of starting HD.Creation of an AVF versus an AVG as the incident arteriovenous access.EXPOSURECreation of an AVF versus an AVG as the incident arteriovenous access.All-cause mortality, all-cause and cause-specific hospitalization, and sepsis.OUTCOMESAll-cause mortality, all-cause and cause-specific hospitalization, and sepsis.Target trial emulation approach, high-dimensional propensity score and inverse probability of treatment weighting, and instrumental variable analysis using the proclivity of the operating physician to create a fistula as the instrumental variable.ANALYTICAL APPROACHTarget trial emulation approach, high-dimensional propensity score and inverse probability of treatment weighting, and instrumental variable analysis using the proclivity of the operating physician to create a fistula as the instrumental variable.A total of 19,867 patients were included, with 80.1% receiving an AVF and 19.9% an AVG. In unweighted analysis, AVF creation was associated with significantly lower risks of mortality and hospitalization, especially within 6 months after vascular access creation. In inverse probability of treatment weighting analysis, AVF creation was associated with lower incidences of mortality and hospitalization within 6 months after creation (hazard ratios of 0.82 [95% CI, 0.75-0.91] and 0.82 [95% CI, 0.78-0.87] for mortality and all-cause hospitalization, respectively), but not between 6 months and 3 years after access creation. No association between AVF creation and mortality, sepsis, or all-cause, cardiovascular disease-related, or infection-related hospitalization was found in instrumental variable analyses. However, AVF creation was associated with a lower risk of access-related hospitalization not due to infection.RESULTSA total of 19,867 patients were included, with 80.1% receiving an AVF and 19.9% an AVG. In unweighted analysis, AVF creation was associated with significantly lower risks of mortality and hospitalization, especially within 6 months after vascular access creation. In inverse probability of treatment weighting analysis, AVF creation was associated with lower incidences of mortality and hospitalization within 6 months after creation (hazard ratios of 0.82 [95% CI, 0.75-0.91] and 0.82 [95% CI, 0.78-0.87] for mortality and all-cause hospitalization, respectively), but not between 6 months and 3 years after access creation. No association between AVF creation and mortality, sepsis, or all-cause, cardiovascular disease-related, or infection-related hospitalization was found in instrumental variable analyses. However, AVF creation was associated with a lower risk of access-related hospitalization not due to infection.Potential for unmeasured confounding, analyses limited to elderly patients, and absence of data on actual access use during follow-up.LIMITATIONSPotential for unmeasured confounding, analyses limited to elderly patients, and absence of data on actual access use during follow-up.Using observational data to emulate a target randomized controlled trial, the type of initial arteriovenous access created was not associated with the risks of mortality, sepsis, or all-cause, cardiovascular disease-related, or infection-related hospitalization among elderly patients who initiated HD with a catheter.CONCLUSIONSUsing observational data to emulate a target randomized controlled trial, the type of initial arteriovenous access created was not associated with the risks of mortality, sepsis, or all-cause, cardiovascular disease-related, or infection-related hospitalization among elderly patients who initiated HD with a catheter. |
| Author | Chan, Micah R Gardezi, Ali Lyu, Beini Yevzlin, Alexander S Astor, Brad C |
| Author_xml | – sequence: 1 givenname: Beini surname: Lyu fullname: Lyu, Beini organization: Department of Population Health Sciences, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin – sequence: 2 givenname: Micah R surname: Chan fullname: Chan, Micah R organization: Department of Medicine, University of Wisconsin School of Medicine and Public Health Madison, Wisconsin – sequence: 3 givenname: Alexander S surname: Yevzlin fullname: Yevzlin, Alexander S organization: Department of Medicine, University of Michigan, Ann Arbor, Michigan – sequence: 4 givenname: Ali surname: Gardezi fullname: Gardezi, Ali organization: Department of Medicine, University of Wisconsin School of Medicine and Public Health Madison, Wisconsin – sequence: 5 givenname: Brad C surname: Astor fullname: Astor, Brad C email: bcastor@medicine.wisc.edu organization: Department of Population Health Sciences, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin; Department of Medicine, University of Wisconsin School of Medicine and Public Health Madison, Wisconsin. Electronic address: bcastor@medicine.wisc.edu |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/34118301$$D View this record in MEDLINE/PubMed |
| BookMark | eNpNkN1Kw0AQhRep2B99AS9kL71o6_4lWb0LpVpBUbRel93stG6bZONuKsTX8IVNawVhYGY435yB00ed0pWA0DklY0oifrUeq_XGjBlhdEx4W-QI9WjE-CiWXHb-zV3UD2FNCLnmcXyCulxQKjmhPfSd-hq8dZ9Qum3AaZZBCHjeVIBVafCLDRvslvjR-Vrltm6GeOZCZXfLl6qtK4d77hWqYNvzwpUrPM0N-LzBMyicsSpvdtJzS0NZhxuc4rnyK6jx3LcinhbbfO-E06ryTmXvp-h4qfIAZ4c-QG-30_lkNnp4urufpA-jTCS8HsVEMaHiTBAtRKIpNxzYkmeCUdDGJJlRUmkmI52QSMZUSJloHmkpNKdKJWyALn9927cfWwj1orAhgzxXJbRhLFgkSERZG2KLXhzQrS7ALCpvC-WbxV-Q7ActGXmp |
| CitedBy_id | crossref_primary_10_1016_j_jvs_2025_07_041 crossref_primary_10_3390_jcm14113981 crossref_primary_10_3390_jcm11133759 crossref_primary_10_1186_s12872_024_03985_x crossref_primary_10_3390_jpm15050195 crossref_primary_10_1177_11297298231196267 crossref_primary_10_3390_medsci12020031 crossref_primary_10_3390_medicina59071294 crossref_primary_10_1016_j_jfma_2024_02_009 crossref_primary_10_1093_ndt_gfad251 crossref_primary_10_1159_000529991 crossref_primary_10_1177_11297298231211361 |
| ContentType | Journal Article |
| Copyright | Copyright © 2021 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved. |
| Copyright_xml | – notice: Copyright © 2021 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved. |
| DBID | CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1053/j.ajkd.2021.03.030 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1523-6838 |
| ExternalDocumentID | 34118301 |
| Genre | Randomized Controlled Trial Journal Article |
| GroupedDBID | --- --K .1- .55 .FO .GJ 0R~ 1B1 1P~ 23M 3O- 4.4 457 4G. 53G 5GY 5RE 5VS 7-5 AAEDT AAEDW AALRI AAQFI AAQQT AAQXK AAWTL AAXUO AAYOK ABCQX ABFRF ABJNI ABLJU ABMAC ABOCM ABWVN ACGFO ACGFS ACRPL ADBBV ADMUD ADNMO ADPAM ADVLN AEFWE AENEX AEVXI AFCTW AFFNX AFJKZ AFRHN AFTJW AGHFR AITUG AJUYK AKRWK ALMA_UNASSIGNED_HOLDINGS AMRAJ ASPBG AVWKF AZFZN BELOY CAG CGR COF CS3 CUY CVF EBS ECM EFJIC EIF EJD EX3 F5P FDB FEDTE FGOYB GBLVA HVGLF HZ~ J5H K-O KOM L7B M41 MO0 N4W NPM O9- OE- P2P PC. PI~ R2- ROL SEL SES SJN SSZ TWZ UNMZH WOW X7M XH2 YCW Z5R ZGI ZXP 7X8 AAFWJ ACVFH ADCNI APXCP EFKBS |
| ID | FETCH-LOGICAL-c473t-60a24a6c40b447b13d3e2f3c421ebdd7cda8ab285b7058614887b35b84b31aa72 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 12 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000734021500012&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1523-6838 |
| IngestDate | Sat Sep 27 21:01:29 EDT 2025 Thu Jan 02 22:56:02 EST 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | hospitalization HD access elderly end-stage renal disease (ESRD) hemodialysis (HD) target trial Arteriovenous access mortality arteriovenous fistula (AVF) arteriovenous graft (AVG) sepsis vascular access |
| Language | English |
| License | Copyright © 2021 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c473t-60a24a6c40b447b13d3e2f3c421ebdd7cda8ab285b7058614887b35b84b31aa72 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Undefined-3 |
| PMID | 34118301 |
| PQID | 2540512523 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_2540512523 pubmed_primary_34118301 |
| PublicationCentury | 2000 |
| PublicationDate | 2022-01-00 20220101 |
| PublicationDateYYYYMMDD | 2022-01-01 |
| PublicationDate_xml | – month: 01 year: 2022 text: 2022-01-00 |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | American journal of kidney diseases |
| PublicationTitleAlternate | Am J Kidney Dis |
| PublicationYear | 2022 |
| SSID | ssj0009366 |
| Score | 2.4398751 |
| Snippet | Evidence is mixed regarding the optimal choice of the first permanent vascular access for elderly patients receiving hemodialysis (HD). Lacking data from... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 69 |
| SubjectTerms | Aged Arteriovenous Shunt, Surgical - adverse effects Hospitalization Humans Kidney Failure, Chronic - therapy Renal Dialysis - adverse effects Retrospective Studies Sepsis - therapy |
| Title | Arteriovenous Access Type and Risk of Mortality, Hospitalization, and Sepsis Among Elderly Hemodialysis Patients: A Target Trial Emulation Approach |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/34118301 https://www.proquest.com/docview/2540512523 |
| Volume | 79 |
| WOSCitedRecordID | wos000734021500012&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LSwMxEA6-EC--H_XFCB67djdJN6kXWaTiwZaiVXoryW4Kbe1udYvg7_APm0lTPAmClz1tYJmdzHu-j5BLm1XRzOYdARcOVFuqQAslA2mkachYhwO3C_PyINpt2es1Or7gVvqxyoVNdIY6K1KskdcohhbWG1N2M30LkDUKu6ueQmOZrDIbyuBIl-j9oIU3mOtVWhfFglgy6ZdmrN7VRldqNEakUBo5kFMW_h5iOldzt_Xfj9wmmz7IhGSuFTtkyeS7ZL3l2-h75CvBQc5h8eEAWiFxpImAKSmoPIPHYTmGYgAtF5rbML0KC3oRv7VZde89mWk5tMeRrwiaSPf9-gn3ZlLgMgoinUBnjtpaXkMCXTdzDl3UeGhOPG0YJB7UfJ883zW7t_eBZ2cIUi7YLIhDRbmKUx5qzoWOWMYMHbCU08joLBNppqTSVNa1COsS8Ual0KyuJdcsUkrQA7KSF7k5IoCYMGEaM02p5lZHlKIa11aYzmTKY1MhFwtx9632Y0tD5cYKqP8j8Ao5nP-z_nQO09G3_tnaqzA6_sPpE7JBca_B1VZOyerA3n1zRtbSj9mwfD93amWf7U7rG2xg18M |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Arteriovenous+Access+Type+and+Risk+of+Mortality%2C+Hospitalization%2C+and+Sepsis+Among+Elderly+Hemodialysis+Patients%3A+A+Target+Trial+Emulation+Approach&rft.jtitle=American+journal+of+kidney+diseases&rft.au=Lyu%2C+Beini&rft.au=Chan%2C+Micah+R&rft.au=Yevzlin%2C+Alexander+S&rft.au=Gardezi%2C+Ali&rft.date=2022-01-01&rft.eissn=1523-6838&rft.volume=79&rft.issue=1&rft.spage=69&rft_id=info:doi/10.1053%2Fj.ajkd.2021.03.030&rft_id=info%3Apmid%2F34118301&rft_id=info%3Apmid%2F34118301&rft.externalDocID=34118301 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1523-6838&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1523-6838&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1523-6838&client=summon |